Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Optimizing treatment approaches for the management of GIST

Margaret von Mehren, MD, Fox Chase Cancer Center, Philadelphia, PA, discusses to work being done to establish the optimal treatment approach for the management of patients with gastrointestinal stromal tumors (GIST). A number of recent FDA approvals have led to questions over the best way to sequence these new agents and several studies are underway assessing this. The management of GIST was revolutionized by the introduction of imatinib, which now represents the standard of care in unresectable or metastatic disease. Despite this, disease progression remains a problem, and more data on how to manage secondary resistance is needed. Dr von Mehren highlights ongoing work looking into novel treatment approaches in the setting of imatinib refractory GIST. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Margaret von Mehren, MD has received research funding from Novartis.